IR Pharma company logo
  • Company overview
  • Meet the team
  • Why we're different;
  • Technology - The drug development process at IRP; The Drug Evaluation Process; Model systems
  • Portfolio
  • Contact us

  • A comprehensive process for the evaluation of respiratory drugs


    IR Pharma will have a presence
    at the following conferences.
    Contact us to arrange
    a meeting with one of the team.

    May 19-24, 2017
    American Thoracic Society
    Annual Conference.
    Washington DC, USA.

    September 9-13, 2017
    European Respiratory Society
    Milan, Italy.

    Four key stages,
    best practice . . .

    IR Pharma can provide a range of models and tests that together provide a comprehensive process for evaluation of respiratory drugs. The process essentially comprises four key stages, which represents current best practice in respiratory drug evaluation and encompasses:

    • Target validation;
    • in vitro profiling;
    • in vivo profiling;
    • pharmacological assessment of key biomarkers.

    In addition to methods for investigating parameters within normal tissue, IR Pharma has developed respiratory disease models tailored to evaluate drug efficacy in:

    • Asthma;
    • COPD;
    • Cough and airway irritancy;
    • Models of pulmonary fibrosis and pulmonary arterial hypertension.

    We believe this combination of assays and models provides a front-line capability for those companies wishing to gain insight into effects and efficacy of drug candidates at the pre-clinical stage.